Blocking KIRs also augments ADCC induced by antibodies binding to CD20 and CD33, suggesting that KIR blockade can enhance the efficacy of therapeutic antibodies that rely on ADCC for killing of cancer cells (206, 208). The gene discussed is KIR3DL1; the disease is cancer.